Dr. Erlinda Grey, M.D
NPI: 1356568752
Total Payments
$6,341
2024 Payments
$542.35
Companies
31
Transactions
375
Medicare Patients
2,365
Medicare Billing
$183,543
Payment Breakdown by Category
Food & Beverage$6,319 (99.7%)
Education$21.70 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,319 | 374 | 99.7% |
| Education | $21.70 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $842.87 | 45 | $0 (2023) |
| SANOFI-AVENTIS U.S. LLC | $613.67 | 30 | $0 (2023) |
| ABBVIE INC. | $597.53 | 33 | $0 (2024) |
| Lilly USA, LLC | $586.06 | 34 | $0 (2024) |
| Novo Nordisk Inc | $485.47 | 32 | $0 (2024) |
| Merck Sharp & Dohme LLC | $390.84 | 25 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $376.41 | 20 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $328.18 | 22 | $0 (2023) |
| IRONWOOD PHARMACEUTICALS, INC | $276.85 | 19 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $260.53 | 13 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $542.35 | 29 | ABBVIE INC. ($146.58) |
| 2023 | $539.64 | 40 | Amgen Inc. ($138.23) |
| 2022 | $636.11 | 32 | Lilly USA, LLC ($144.30) |
| 2021 | $716.82 | 42 | AbbVie Inc. ($211.15) |
| 2020 | $347.50 | 22 | Lilly USA, LLC ($67.65) |
| 2019 | $624.11 | 43 | SANOFI-AVENTIS U.S. LLC ($143.61) |
| 2018 | $1,024 | 63 | Amgen Inc. ($257.37) |
| 2017 | $1,910 | 104 | Amgen Inc. ($424.44) |
All Payment Transactions
375 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Gastroenterology | ||||||
| 12/02/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $20.43 | General |
| Category: Endocrinology | ||||||
| 11/26/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), VAXNEUVANCE, CAPVAXIVE | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: VACCINE | ||||||
| 11/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Cardio-renal | ||||||
| 11/11/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/04/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Endocrinology | ||||||
| 11/01/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $34.85 | General |
| Category: Diabetes | ||||||
| 10/31/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/24/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Obesity | ||||||
| 10/11/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $16.45 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/19/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $10.74 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/16/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $30.82 | General |
| Category: Diabetes | ||||||
| 09/05/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $16.01 | General |
| Category: PSYCHIATRY | ||||||
| 08/13/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/28/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/16/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $25.72 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 05/08/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $22.35 | General |
| Category: Endocrinology | ||||||
| 05/02/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Diabetes | ||||||
| 04/25/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/17/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $11.28 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/11/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.67 | General |
| Category: PSYCHIATRY | ||||||
| 04/02/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Diabetes | ||||||
| 03/20/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.55 | General |
| Category: Diabetes | ||||||
| 03/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 478 | 1,026 | $77,390 | $41,190 |
| 2022 | 7 | 624 | 1,112 | $83,210 | $47,499 |
| 2021 | 8 | 667 | 1,223 | $99,985 | $53,530 |
| 2020 | 11 | 596 | 974 | $87,400 | $41,324 |
Total Patients
2,365
Total Services
4,335
Medicare Billing
$183,543
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 166 | 569 | $34,140 | $22,817 | 66.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 127 | 164 | $13,120 | $7,662 | 58.4% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 61 | 139 | $13,900 | $4,663 | 33.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 91 | 112 | $13,440 | $4,627 | 34.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 15 | 15 | $2,250 | $1,097 | 48.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 27 | $540.00 | $324.22 | 60.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 243 | 413 | $33,040 | $20,694 | 62.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 160 | 439 | $26,340 | $18,772 | 71.3% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2022 | 74 | 82 | $9,840 | $3,366 | 34.2% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2022 | 67 | 85 | $8,500 | $2,593 | 30.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 27 | 27 | $4,050 | $1,583 | 39.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 31 | 42 | $840.00 | $488.73 | 58.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 22 | 24 | $600.00 | $1.97 | 0.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 276 | 572 | $45,760 | $27,361 | 59.8% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 123 | 283 | $16,980 | $11,637 | 68.5% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2021 | 86 | 114 | $13,680 | $4,959 | 36.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 53 | 53 | $7,950 | $4,544 | 57.2% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2021 | 77 | 134 | $13,400 | $4,419 | 33.0% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 20 | 30 | $600.00 | $356.44 | 59.4% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 19 | 20 | $1,190 | $250.80 | 21.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 13 | 17 | $425.00 | $1.76 | 0.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 171 | 440 | $35,200 | $21,960 | 62.4% |
| G0180 | Physician certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial implem | Office | 2020 | 109 | 130 | $15,600 | $5,140 | 32.9% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 62 | 101 | $6,060 | $3,699 | 61.0% |
| G0179 | Physician re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians to affirm the initial imp | Office | 2020 | 70 | 103 | $10,300 | $3,277 | 31.8% |
About Dr. Erlinda Grey, M.D
Dr. Erlinda Grey, M.D is a Medical Genetics, Ph.D. Medical Genetics healthcare provider based in Panorama City, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1356568752.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Erlinda Grey, M.D has received a total of $6,341 in payments from pharmaceutical and medical device companies, with $542.35 received in 2024. These payments were reported across 375 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($6,319).
As a Medicare-enrolled provider, Grey has provided services to 2,365 Medicare beneficiaries, totaling 4,335 services with total Medicare billing of $183,543. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Genetics, Ph.D. Medical Genetics
- Other Specialties Ph.D. Medical Genetics
- Location Panorama City, CA
- Active Since 04/19/2007
- Last Updated 03/19/2014
- Taxonomy Code 170100000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1356568752
Products in Payments
- LINZESS (Drug) $457.63
- Repatha (Biological) $450.51
- JARDIANCE (Drug) $435.90
- TOUJEO (Drug) $283.29
- RELISTOR ORAL (Drug) $232.13
- Prolia (Biological) $229.93
- JANUVIA (Drug) $177.20
- XIFAXAN (Drug) $166.17
- Movantik (Drug) $158.87
- SOLIQUA 100/33 (Biological) $157.73
- TRULICITY (Drug) $157.31
- BELSOMRA (Drug) $148.39
- MOUNJARO (Drug) $143.27
- Victoza (Drug) $137.37
- Linzess (Drug) $117.55
- MOVANTIK (Drug) $108.75
- Creon (Drug) $104.44
- Otezla (Drug) $99.61
- Dexcom G6 Transmitter (Medical Supply) $96.63
- Ozempic (Drug) $77.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.